{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:13:17Z","timestamp":1762254797095,"version":"build-2065373602"},"reference-count":196,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443141645"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 265","2020"],"award-info":[{"award-number":["TRR 265","2020"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX01909"],"award-info":[{"award-number":["01ZX01909"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.03.005","type":"book-chapter","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T09:42:17Z","timestamp":1710582137000},"page":"187-239","source":"Crossref","is-referenced-by-count":4,"title":["Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2024.03.005_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of \u03b3-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib2","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1073\/pnas.1204376109","article-title":"4 GABAA receptors are high-affinity targets for-hydroxybutyric acid (GHB)","volume":"109","author":"Absalom","year":"2012","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.irn.2024.03.005_bib3","first-page":"1596","article-title":"Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine","volume":"23","author":"Addolorato","year":"1999","journal-title":"Alcoholism, Clinical and Experimental Research."},{"key":"10.1016\/bs.irn.2024.03.005_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.03.005_bib5","doi-asserted-by":"crossref","first-page":"276.e13","DOI":"10.1016\/j.amjmed.2005.08.042","article-title":"Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam","volume":"119","author":"Addolorato","year":"2006","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/bs.irn.2024.03.005_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14740338.2020.1709821","article-title":"Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects","volume":"19","author":"Addolorato","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/bs.irn.2024.03.005_bib8","article-title":"Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects","volume":"26","author":"Addolorato","year":"2019"},{"key":"10.1016\/bs.irn.2024.03.005_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1530-0277.1994.tb00053.x","article-title":"Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: Preliminary findings","volume":"18","author":"Adinoff","year":"1994","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib10","article-title":"Baclofen for alcohol use disorder","volume":"2023","author":"Agabio","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2024.03.005_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005063.pub3","article-title":"Benzodiazepines for alcohol withdrawal","author":"Amato","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2024.03.005_bib12","unstructured":"ANSM\u2014CSST (2018). Evaluation of the benefit\/risk ratio of the use of baclofen in alcohol-dependent patients. Statement of opinion."},{"key":"10.1016\/bs.irn.2024.03.005_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/alcalc\/agab003","article-title":"Recent advances in the potential of positive allosteric modulators of the GABAB receptor to treat alcohol use disorder","volume":"56","author":"Augier","year":"2021","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","article-title":"Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis","volume":"16","author":"Bahji","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/add.15853","article-title":"Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: A systematic review and network meta\u2010analysis","author":"Bahji","year":"2022","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bcp.2013.10.028","article-title":"GHB receptor targets in the CNS: Focus on high-affinity binding sites","volume":"87","author":"Bay","year":"2014","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib17","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","article-title":"Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial","volume":"26","author":"Beraha","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib18","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/dar.12659","article-title":"Implementing managed alcohol programs in hospital settings: A review of academic and grey literature","volume":"37","author":"Brooks","year":"2018","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/bs.irn.2024.03.005_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder-a systematic meta-analysis","volume":"138","author":"Bschor","year":"2018","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/bs.irn.2024.03.005_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/bs.irn.2024.03.005_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(02)00340-X","article-title":"Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: An open randomized comparative study","volume":"70","author":"Caputo","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.03.005_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","article-title":"Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study","volume":"17","author":"Caputo","year":"2007","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.euroneuro.2010.12.005","article-title":"Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity","volume":"21","author":"Caputo","year":"2011","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881108094620","article-title":"Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: An open comparative study","volume":"23","author":"Caputo","year":"2009","journal-title":"Journal Psychopharmacology (Oxford)"},{"key":"10.1016\/bs.irn.2024.03.005_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-014-0183-1","article-title":"Sodium oxybate in the treatment of alcohol withdrawal syndrome: A randomized double-blind comparative study versus oxazepam. The GATE 1 Trial","volume":"28","author":"Caputo","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.irn.2024.03.005_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(02)01502-9","article-title":"Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid","volume":"441","author":"Carai","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.04.012","article-title":"Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem\u00ae): Differences in characteristics and misuse","volume":"104","author":"Carter","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.03.005_bib29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pds.4635","article-title":"Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France","volume":"27","author":"Chaignot","year":"2018","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/bs.irn.2024.03.005_bib30","first-page":"m3934","article-title":"Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis","author":"Cheng","year":"2020","journal-title":"BMJ (Clinical Research ed.)"},{"key":"10.1016\/bs.irn.2024.03.005_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","article-title":"Substitution therapy for alcoholism: Time for a reappraisal?","volume":"26","author":"Chick","year":"2012","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1530-0277.2011.01675.x","article-title":"Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements: VARENCILINE EFFECTS ON ALCOHOL RESPONSES","volume":"36","author":"Childs","year":"2012","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0031-9384(94)00215-Q","article-title":"Symmetrical generalization between the discriminative stimulus effects of gamma-hydroxybutyric acid and ethanol: Occurrence within narrow dose ranges","volume":"57","author":"Colombo","year":"1995","journal-title":"Physiology & Behavior"},{"key":"10.1016\/bs.irn.2024.03.005_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1369-1600.2000.tb00207.x","article-title":"Gamma-hydroxybutyric acid in alcohol preference, dependence and withdrawal","volume":"5","author":"Colombo","year":"2000","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079062","article-title":"\u03b3-Hydroxybutyric Acid (GHB) is not an agonist of extrasynaptic GABAA receptors","volume":"8","author":"Connelly","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2024.03.005_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"AJP"},{"key":"10.1016\/bs.irn.2024.03.005_bib37","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1038\/s41467-019-13162-w","article-title":"Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories","volume":"10","author":"Das","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2024.03.005_bib38","first-page":"179","article-title":"Alcohol\u2019s actions on neuronal nicotinic acetylcholine receptors","volume":"29","author":"Davis","year":"2006","journal-title":"Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib39","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/add.15647","article-title":"Clinical management of the alcohol withdrawal syndrome","volume":"117","author":"Day","year":"2022","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib40","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/acer.12854","article-title":"Varenicline for treatment of alcohol dependence: A randomized, placebo-controlled trial","volume":"39","author":"de Bejczy","year":"2015","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib41","first-page":"111","article-title":"Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol-dependent patients","volume":"7","author":"Di Bello","year":"1995","journal-title":"Alcologia"},{"key":"10.1016\/bs.irn.2024.03.005_bib42","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/acer.14674","article-title":"Alcohol use disorder severity moderates clinical response to varenicline","volume":"45","author":"Donato","year":"2021","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib43","unstructured":"Drugbank (2023). Ethanol (DB00898). In DrugBank. \u3008https:\/\/go.drugbank.com\/drugs\/DB00898\u3009.\u00a0Accessed 11.07.23."},{"key":"10.1016\/bs.irn.2024.03.005_bib44","unstructured":"Drugbank (2015). Sodium oxybate.\u00a0In Drugbank\u00a0\u3008https:\/\/go.drugbank.com\/drugs\/DB09072\u3009\u00a0Accessed 31.03.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jpsychires.2023.06.042","article-title":"Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases","volume":"164","author":"Duan","year":"2023","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib46","unstructured":"European Medicines Agency (2021). Pharmacovigilance risk assessment committee (PRAC). Minutes for the meeting on 03\u201306 May 2021. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-3\u20136-may-2021_.pdf\u3009 Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib47","unstructured":"European Medicines Agency (2020a). Assessment report\u2014Hopveus\u2014Procedure No. EMEA\/H\/C\/004962\/0000."},{"key":"10.1016\/bs.irn.2024.03.005_bib48","unstructured":"European Medicines Agency (2020b). Pharmacovigilance risk assessment committee (PRAC). Minutes of the meeting on 11\u201314 May 2020. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-11\u201314-may-2020_en.pdf\u3009 Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib49","unstructured":"European Medicines Agency (2019). Pharmacovigilance risk assessment committee (PRAC). Minutes of PRAC meeting on 13\u201316 May 2019. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-13\u201316-may-2019_en.pdf\u3009\u00a0Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib50","unstructured":"European Medicines Agency (2018). Pharmacovigilance risk assessment committee (PRAC). Minutes of PRAC meeting on 14\u201317 May 2018. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-14\u201317-may-2018_en.pdf\u3009\u00a0Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib51","unstructured":"European Medicines Agency (2017). Pharmacovigilance risk assessment committee (PRAC). Minutes of the meeting on 6\u20139 June 2017. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-6\u20139-june-2017_en.pdf\u3009\u00a0Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib52","unstructured":"European Medicines Agency (2016). Pharmacovigilance risk assessment committee (PRAC). Minutes of PRAC meeting on 10\u201313 May 2016. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-10\u201313-may-2016_en.pdf\u3009\u00a0Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib53","unstructured":"European Medicines Agency (2010). Guideline on the development of medicinal products for the treatment of alcohol dependence. EMA\/CHMP\/EWP\/20097\/2008 \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-development-medicinal-products-treatment-alcohol-dependence_en.pdf\u3009 Accessed 4.03.21."},{"key":"10.1016\/bs.irn.2024.03.005_bib54","unstructured":"European Medicines Agency (2006). EPAR Xyrem\u2014scientific discussion. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/xyrem-epar-scientific-discussion_en.pdf\u3009 Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1530-0277.2007.00360.x","article-title":"A pilot double-blind treatment trial of memantine for alcohol dependence","volume":"31","author":"Evans","year":"2007","journal-title":"Alcoholism Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib56","first-page":"162","article-title":"An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: Findings from the national epidemiologic survey on alcohol and related conditions","volume":"29","author":"Falk","year":"2006","journal-title":"Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hup.718","article-title":"Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome","volume":"20","author":"Favre","year":"2005","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/bs.irn.2024.03.005_bib58","unstructured":"FDA (2013). Guidance for industry\u2014Codevelopment of two or more new investigational drugs for use in combination."},{"key":"10.1016\/bs.irn.2024.03.005_bib59","unstructured":"FDA (2005). Estimating the maximum starting dose in initial clinical trials for therapeutics in adult healthy volunteers 30."},{"key":"10.1016\/bs.irn.2024.03.005_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2016.00114","article-title":"Potentiation of gamma aminobutyric acid receptors (GABAAR) by ethanol: How are inhibitory receptors affected?","volume":"10","author":"F\u00f6rstera","year":"2016","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2024.03.005_bib61","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/acer.13157","article-title":"Combining varenicline (Chantix) with naltrexone decreases alcohol drinking more effectively than does either drug alone in a rodent model of alcoholism","volume":"40","author":"Froehlich","year":"2016","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib62","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4037\/ajcc2013283","article-title":"Alcohol withdrawal prevention: A randomized evaluation of lorazepam and ethanol--a pilot study","volume":"22","author":"Fullwood","year":"2013","journal-title":"American Journal of Critical Care"},{"key":"10.1016\/bs.irn.2024.03.005_bib63","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(89)90842-8","article-title":"Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome","author":"Gallimberti","year":"1989","journal-title":"Lancet 2"},{"key":"10.1016\/bs.irn.2024.03.005_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/npp.1993.45","article-title":"Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome","volume":"9","author":"Gallimberti","year":"1993","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/bs.irn.2024.03.005_bib65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","article-title":"Gamma-hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study","volume":"16","author":"Gallimberti","year":"1992","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/alcalc\/agz084","article-title":"Approval of baclofen for alcohol use disorders in France: A perspective from the United States","volume":"55","author":"Garbutt","year":"2020","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.03.005_bib67","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib68","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","article-title":"Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: A dose-response, randomized, controlled trial","volume":"46","author":"Garbutt","year":"2021","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib69","series-title":"StatPearls","article-title":"Baclofen","author":"Ghanavatian","year":"2023"},{"key":"10.1016\/bs.irn.2024.03.005_bib70","first-page":"11","article-title":"Neurobiology of alcohol dependence","volume":"31","author":"Gilpin","year":"2008","journal-title":"Neurobiology of Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.03.005_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bj.2015.09.002","article-title":"A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome","volume":"39","author":"Girish","year":"2016","journal-title":"Biomedical Journal"},{"key":"10.1016\/bs.irn.2024.03.005_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/jama.1967.03130020045009","article-title":"Comparative evaluation of treatments of alcohol withdrawal syndromes","volume":"201","author":"Golbert","year":"1967","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.03.005_bib73","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1532-5415.2010.03048.x","article-title":"Once-daily memantine: Pharmacokinetic and clinical considerations","volume":"58","author":"Gomolin","year":"2010","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1016\/bs.irn.2024.03.005_bib74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"AJP"},{"issue":"Suppl. 2","key":"10.1016\/bs.irn.2024.03.005_bib75","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1046\/j.1360-0443.95.8s2.1.x","article-title":"The tonic\/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving","volume":"95","author":"Grace","year":"2000","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib76","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-3565(25)10137-7","article-title":"Discriminative stimulus effects of ethanol: Effect of training dose on the substitution of N-methyl-D-aspartate antagonists","volume":"264","author":"Grant","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2024.03.005_bib77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002130000510","article-title":"Characterization of the discriminative stimulus effects of GABA(A) receptor ligands in Macaca fascicularis monkeys under different ethanol training conditions","volume":"152","author":"Grant","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib78","unstructured":"Guiraud, J. (2023). Sodium oxybate for the treatment of alcohol dependence. University of Amsterdam ed. \u3008https:\/\/hdl.handle.net\/11245.1\/ad0b0a9e-e28c-432d-81a9-ccdf39b190f8\u3009 Accessed 21.05.23."},{"key":"10.1016\/bs.irn.2024.03.005_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/02698811221104063","article-title":"Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial","author":"Guiraud","year":"2022","journal-title":"Journal of Psychopharmacology 2698811221104063"},{"key":"10.1016\/bs.irn.2024.03.005_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agac070","article-title":"Sodium oxybate for alcohol dependence: A network meta-regression analysis considering population severity at baseline and treatment duration","author":"Guiraud","year":"2023","journal-title":"Alcohol and Alcoholism agac070"},{"key":"10.1016\/bs.irn.2024.03.005_bib81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2021.06.003","article-title":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study","volume":"52","author":"Guiraud","year":"2021","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib82","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/bs.irn.2024.03.005_bib83","first-page":"31","article-title":"Discriminative stimulus effects of diazepam, ketamine and their mixture: Ethanol substitution patterns","volume":"9","author":"Harrison","year":"1998","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib84","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial: Baclofen for AUD in veterans with HCV","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib85","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2044.1982.tb01810.x","article-title":"The alcoholic patient and surgical stress","volume":"37","author":"Haxholdt","year":"1982","journal-title":"Anaesthesia"},{"key":"10.1016\/bs.irn.2024.03.005_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12866","article-title":"Addiction research consortium: Losing and regaining control over drug intake (ReCoDe)\u2014From trajectories to mechanisms and interventions","volume":"25","author":"Heinz","year":"2020","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib87","unstructured":"Hornfeldt, C. S., Lothriddge, K., Upshaw Downs, J. C. (2002). Forensic science update: Gamma-Hydroxybutyrate (GHB), Hornfeldt, Lothridge, and Downs (Forensic Science Communications, January 2002). FBI. \u3008https:\/\/www.fbi.gov\/about-us\/lab\/forensic-science-communications\/fsc\/jan2002\/hornfelt.htm\u3009 Accessed 24.5.18."},{"key":"10.1016\/bs.irn.2024.03.005_bib88","article-title":"Alcohol-binding sites in distinct brain proteins: The quest for atomic level resolution","author":"Howard","year":"2011","journal-title":"Alcoholism Clinical and Experimental Research 35, 1561\u20131573"},{"key":"10.1016\/bs.irn.2024.03.005_bib89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s002130050484","article-title":"Ethanol and N-methyl-D-aspartate receptor complex interactions: A detailed drug discrimination study in the rat","volume":"135","author":"Hundt","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2017.11.017","article-title":"Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial","volume":"184","author":"Hurt","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.03.005_bib91","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00213-002-1294-9","article-title":"Lorazepam substitutes for the alcohol stimulus in social drinkers","volume":"166","author":"Jackson","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib92","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s002130100817","article-title":"A low dose alcohol drug discrimination in social drinkers: Relationship with subjective effects","volume":"157","author":"Jackson","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib93","first-page":"482","article-title":"A double blind study for efficacy of diazepam and baclofen in the treatment of alcohol withdrawal syndrome","volume":"4","author":"Jhanwar","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2024.03.005_bib94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1037\/a0031692","article-title":"Comparative abuse liability of GHB and ethanol in humans","volume":"21","author":"Johnson","year":"2013","journal-title":"Exp Clin Psychopharmacol."},{"key":"10.1016\/bs.irn.2024.03.005_bib95","unstructured":"Kamal, R. M. (2016). The detoxification approach for patients with GHB dependence. [S.l.: s.n.] \u3008https:\/\/repository.ubn.ru.nl\/bitstream\/handle\/2066\/151486\/151486.pdf?sequence=1\u3009 Accessed 5.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib96","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443173","article-title":"The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: A review","volume":"73","author":"Kamal","year":"2016","journal-title":"Neuropsychobiology"},{"key":"10.1016\/bs.irn.2024.03.005_bib97","unstructured":"Kaplan, W., Wirtz, V. J., Mantel-Teeuwisse, A., Stolk, P., Duthey, B., & Laing, R. (2013). Priority medicines for Europe and the World\u20142013 update."},{"key":"10.1016\/bs.irn.2024.03.005_bib98","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0972-6748.132914","article-title":"Clinical management of alcohol withdrawal: A systematic review","volume":"22","author":"Kattimani","year":"2013","journal-title":"Industrial Psychiatry Journal"},{"key":"10.1016\/bs.irn.2024.03.005_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","article-title":"Sodium oxybate: A review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence","volume":"34","author":"Keating","year":"2014","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/bs.irn.2024.03.005_bib100","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.38498","article-title":"Ketamine treatment for alcohol use disorder: A systematic review","author":"Kelson","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/bs.irn.2024.03.005_bib101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12868-019-0540-6","article-title":"Diazepam and ethanol differently modulate neuronal activity in organotypic cortical cultures","volume":"20","author":"Kreuzer","year":"2019","journal-title":"BMC Neuroscience"},{"key":"10.1016\/bs.irn.2024.03.005_bib102","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/acer.12619","article-title":"N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers","volume":"39","author":"Krishnan-Sarin","year":"2015","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib103","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11055-016-0379-6","article-title":"Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study)","volume":"47","author":"Krupitskii","year":"2017","journal-title":"Neuroscience and Behavioral Physiology"},{"key":"10.1016\/bs.irn.2024.03.005_bib104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1300\/J020V09N01_09","article-title":"The combination of psychedelic and aversive approaches in alcoholism treatment: The affective contra-attribution method","volume":"9","author":"Krupitsky","year":"1992","journal-title":"Alcoholism Treatment Quarterly"},{"key":"10.1016\/bs.irn.2024.03.005_bib105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1176\/ajp.2007.164.3.519","article-title":"Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients","volume":"164","author":"Krupitsky","year":"2007","journal-title":"AJP"},{"key":"10.1016\/bs.irn.2024.03.005_bib106","doi-asserted-by":"crossref","DOI":"10.1111\/j.1530-0277.2007.00344.x","article-title":"Antiglutamatergic strategies for ethanol detoxification: Comparison with placebo and diazepam","author":"Krupitsky","year":"2007","journal-title":"Alcoholism: Clinical and Experimental Research 0"},{"key":"10.1016\/bs.irn.2024.03.005_bib107","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.npp.1300252","article-title":"Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients","volume":"28","author":"Krystal","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib108","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archpsyc.55.4.354","article-title":"Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics","volume":"55","author":"Krystal","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13098","article-title":"Changes in interoception after alcohol administration correlate with expectancies and subjective effects","volume":"27","author":"Leganes-Fonteneau","year":"2022","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/alcalc\/agx072","article-title":"Baclofen self-poisoning in the era of changing indication: Multicentric reports to a french poison control centre","volume":"52","author":"L\u00e9ger","year":"2017","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/alcalc\/33.6.563","article-title":"Benzodiazepine treatment for alcohol-dependent patients","volume":"33","author":"Lejoyeux","year":"1998","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006266.pub2","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","author":"Leone","year":"2010","journal-title":"Cochrane Database of Systematic Reviews CD006266"},{"year":"2003","series-title":"Principles of forensic toxicology","author":"Levine","key":"10.1016\/bs.irn.2024.03.005_bib113"},{"key":"10.1016\/bs.irn.2024.03.005_bib114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/10550887.2020.1721404","article-title":"Randomized trial to assess safety\/feasibility of memantine administration during residential treatment for alcohol use disorder: a pilot study","volume":"38","author":"Lewis","year":"2020","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/bs.irn.2024.03.005_bib115","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib116","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008502.pub6","article-title":"Baclofen for alcohol withdrawal","author":"Liu","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2024.03.005_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108807","article-title":"Interoception and alcohol: Mechanisms, networks, and implications","volume":"200","author":"Lovelock","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib119","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1126\/science.2467382","article-title":"Ethanol inhibits NMDA-activated ion current in hippocampal neurons","volume":"243","author":"Lovinger","year":"1989","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2024.03.005_bib120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jhm.928","article-title":"Treating alcohol withdrawal with oral baclofen: A randomized, double-blind, placebo-controlled trial","volume":"6","author":"Lyon","year":"2011","journal-title":"Journal of Hospital Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib121","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0376-8716(00)00238-6","article-title":"Self-administered ethanol as a discriminative stimulus in rats","volume":"64","author":"Macenski","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.03.005_bib122","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11606-002-0038-1","article-title":"The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial","volume":"17","author":"Malcolm","year":"2002","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib123","first-page":"236","article-title":"Actions and interactions with alcohol of drugs on psychomotor skills: Comparison of diazepam and gamma-hydroxybutyric acid","volume":"234","author":"Mattila","year":"1978","journal-title":"Archives Internationales de Pharmacodynamie et de Therapie"},{"key":"10.1016\/bs.irn.2024.03.005_bib124","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers","volume":"66","author":"McKee","year":"2009","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib125","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.amp.2020.12.020","article-title":"Traitement de substitution alcoolique. Quelle place pour les benzodiaz\u00e9pines","volume":"180","author":"Menecier","year":"2022","journal-title":"Annales M\u00e9dico-psychologiques, revue psychiatrique"},{"key":"10.1016\/bs.irn.2024.03.005_bib126","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/acer.14352","article-title":"Effects of alcohol cue reactivity on subsequent treatment outcomes among treatment-seeking individuals with alcohol use disorder: A multisite randomized, double-blind, placebo-controlled clinical trial of varenicline","volume":"44","author":"Miranda","year":"2020","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcrc.2015.11.022","article-title":"Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials","volume":"32","author":"Mo","year":"2016","journal-title":"Journal of Critical Care"},{"key":"10.1016\/bs.irn.2024.03.005_bib129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00441-006-0284-3","article-title":"GABAA receptor diversity and pharmacology","volume":"326","author":"M\u00f6hler","year":"2006","journal-title":"Cell and Tissue Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0741-8329(99)00093-2","article-title":"Gamma-hydroxybutyric acid and alcohol-related syndromes","volume":"20","author":"Moncini","year":"2000","journal-title":"Alcohol (Fayetteville, N. Y.)"},{"key":"10.1016\/bs.irn.2024.03.005_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110409","article-title":"Mechanistic insights into the efficacy of memantine in treating certain drug addictions","volume":"111","author":"Montemitro","year":"2021","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib132","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: Multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib133","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","volume":"49","author":"Morley","year":"2014","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.03.005_bib134","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4088\/JCP.v69n0308","article-title":"Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence","volume":"69","author":"Muhonen","year":"2008","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","article-title":"High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial","volume":"25","author":"M\u00fcller","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib136","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/add.15109","article-title":"Restoring the bacloville trial: Efficacy and harms","volume":"115","author":"Naudet","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib137","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00952990701315046","article-title":"Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: An open study vs. diazepam","volume":"33","author":"Nava","year":"2007","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/bs.irn.2024.03.005_bib138","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02791072.2006.10399846","article-title":"Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions","volume":"38","author":"Nava","year":"2006","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.irn.2024.03.005_bib139","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/alcalc\/37.1.67","article-title":"Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal","volume":"37","author":"Nimmerrichter","year":"2002","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.03.005_bib140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s42003-018-0157-9","article-title":"Alcohol reduces muscle fatigue through atomistic interactions with nicotinic receptors","volume":"1","author":"Noori","year":"2018","journal-title":"Communications Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib141","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13041-017-0325-8","article-title":"Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model","volume":"10","author":"Olsen","year":"2017","journal-title":"Molecular Brain"},{"key":"10.1016\/bs.irn.2024.03.005_bib142","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamapsychiatry.2017.3544","article-title":"Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: A randomized clinical trial","volume":"75","author":"O\u2019Malley","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/bs.irn.2024.03.005_bib143","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","volume":"113","author":"Palpacuer","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib144","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-014-0163-5","article-title":"Inpatient management of acute alcohol withdrawal syndrome","volume":"28","author":"Perry","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.irn.2024.03.005_bib145","article-title":"Efficacy and safety of baclofen for treatment of alcohol dependence: An updated meta-analysis and meta-regression study","volume":"84","author":"Phimarn","year":"2022","journal-title":"IJPS"},{"key":"10.1016\/bs.irn.2024.03.005_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis","author":"Pierce","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib147","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1097\/CCM.0000000000003204","article-title":"Adjunct ketamine use in the management of severe ethanol withdrawal","volume":"46","author":"Pizon","year":"2018","journal-title":"Critical Care Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib148","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.drugalcdep.2013.06.019","article-title":"Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence","volume":"133","author":"Plebani","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.03.005_bib149","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1503\/cmaj.1041350","article-title":"Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol","volume":"174","author":"Podymow","year":"2006","journal-title":"CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne"},{"key":"10.1016\/bs.irn.2024.03.005_bib150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","article-title":"Baclofen as add-on to standard psychosocial treatment for alcohol dependence: A randomized, double-blind, placebo-controlled trial With 1-year follow-up","volume":"52","author":"Ponizovsky","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/bs.irn.2024.03.005_bib151","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/ijms21072471","article-title":"Residues in transmembrane segments of the P2X4 receptor contribute to channel function and ethanol sensitivity","volume":"21","author":"Popova","year":"2020","journal-title":"International Journal of Molecular Science"},{"key":"10.1016\/bs.irn.2024.03.005_bib152","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00008877-200411000-00006","article-title":"Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers","volume":"15","author":"Poulos","year":"2004","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib153","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bcp.12632","article-title":"Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers","volume":"80","author":"Pross","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112196","article-title":"Meta-analysis of alcohol induced gut dysbiosis and the resulting behavioral impact","volume":"376","author":"Qamar","year":"2019","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib155","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s00213-016-4354-2","article-title":"The nicotine + alcohol interoceptive drug state: Contribution of the components and effects of varenicline in rats","volume":"233","author":"Randall","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib156","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12725","article-title":"Pharmacological targeting of the GABA B receptor alters Drosophila\u2019s behavioural responses to alcohol","volume":"25","author":"Ranson","year":"2020","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib157","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent Patients\u2014The ALPADIR study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib158","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/add.14927","article-title":"Titrated baclofen for high\u2010risk alcohol consumption: A randomized placebo\u2010controlled trial in out\u2010patients with 1\u2010year follow\u2010up","volume":"115","author":"Rigal","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib159","doi-asserted-by":"crossref","first-page":"44729","DOI":"10.1074\/jbc.M102800200","article-title":"Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue","volume":"276","author":"Ronald","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.irn.2024.03.005_bib160","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14191","article-title":"Baclofen: Its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis","volume":"113","author":"Rose","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib161","series-title":"StatPearls","article-title":"Ketamine","author":"Rosenbaum","year":"2023"},{"key":"10.1016\/bs.irn.2024.03.005_bib162","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/0269881120970879","article-title":"Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial","volume":"35","author":"Rothberg","year":"2021","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib163","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1097\/CCM.0b013e3181ec5412","article-title":"Alcohol withdrawal syndromes in the intensive care unit","volume":"38","author":"Sarff","year":"2010","journal-title":"Critical Care Medicine"},{"key":"10.1016\/bs.irn.2024.03.005_bib164","doi-asserted-by":"crossref","DOI":"10.1111\/acer.14670","article-title":"Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta\u2010regression analysis to develop an enrichment strategy","author":"Scherrer","year":"2021","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s13181-018-0662-8","article-title":"Adjunctive use of ketamine for benzodiazepine-resistant severe alcohol withdrawal: A retrospective evaluation","volume":"14","author":"Shah","year":"2018","journal-title":"Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology"},{"key":"10.1016\/bs.irn.2024.03.005_bib166","first-page":"441","article-title":"Ethanol drug discrimination in rats: Substitution with GABA agonists and NMDA antagonists","volume":"5","author":"Shelton","year":"1994","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib167","series-title":"StatPearls","article-title":"Varenicline","author":"Singh","year":"2023"},{"key":"10.1016\/bs.irn.2024.03.005_bib168","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: From the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/bs.irn.2024.03.005_bib169","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12954-022-00646-0","article-title":"Scoping review of managed alcohol programs","volume":"19","author":"Smith-Bernardin","year":"2022","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/bs.irn.2024.03.005_bib170","unstructured":"Sobrera (2023). Press release: Both primary endpoints successfully met in Phase 2 trial for patients with Alcohol Use Disorder (AUD)."},{"key":"10.1016\/bs.irn.2024.03.005_bib171","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12807","article-title":"Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats","volume":"25","author":"S\u00f6derpalm","year":"2020","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib172","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1152\/physrev.00013.2008","article-title":"Alcoholism: A systems approach from molecular physiology to addictive behavior","volume":"89","author":"Spanagel","year":"2009","journal-title":"Physiological Reviews"},{"key":"10.1016\/bs.irn.2024.03.005_bib173","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tins.2014.02.006","article-title":"Stress and alcohol interactions: Animal studies and clinical significance","volume":"37","author":"Spanagel","year":"2014","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/bs.irn.2024.03.005_bib174","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(99)01447-2","article-title":"The dopamine hypothesis of reward: Past and current status","volume":"22","author":"Spanagel","year":"1999","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/bs.irn.2024.03.005_bib175","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/bja\/75.6.734","article-title":"Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection","volume":"75","author":"Spies","year":"1995","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/bs.irn.2024.03.005_bib176","doi-asserted-by":"crossref","DOI":"10.1111\/dar.12618","article-title":"Does managing the consumption of people with severe alcohol dependence reduce harm? A comparison of participants in six Canadian managed alcohol programs with locally recruited controls","volume":"37","author":"Stockwell","year":"2018","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/bs.irn.2024.03.005_bib177","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/alcalc\/agaa134","article-title":"Trajectories of alcohol use and related harms for managed alcohol program participants over 12 months compared with local controls: A quasi-experimental study","volume":"56","author":"Stockwell","year":"2021","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.03.005_bib178","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000480380","article-title":"Comparison of clomethiazole and diazepam in the treatment of alcohol withdrawal syndrome in clinical practice","volume":"23","author":"Sychla","year":"2017","journal-title":"European Addiction Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib179","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","article-title":"GHB and ethanol effects and interactions in humans.","volume":"26","author":"Thai","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.03.005_bib180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/ph6020251","article-title":"NMDA receptor modulators in the treatment of drug addiction","volume":"6","author":"Tomek","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/bs.irn.2024.03.005_bib181","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00508-017-1299-3","article-title":"S(+)-ketamine: Current trends in emergency and intensive care medicine.","volume":"130","author":"Trimmel","year":"2018","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1016\/bs.irn.2024.03.005_bib182","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tips.2014.04.009","article-title":"Alcohol dependence: Molecular and behavioral evidence","volume":"35","author":"Trudell","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2024.03.005_bib183","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12954-016-0103-4","article-title":"Do managed alcohol programs change patterns of alcohol consumption and reduce related harm? A pilot study","volume":"13","author":"Vallance","year":"2016","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/bs.irn.2024.03.005_bib184","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/0269881115581980","article-title":"European rating of drug harms","volume":"29","author":"Van Amsterdam","year":"2015","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2024.03.005_bib185","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","article-title":"Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level","volume":"23","author":"van den Brink","year":"2018","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.03.005_bib186","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/acer.13110","article-title":"Effect of varenicline combined with high-dose alcohol on craving, subjective intoxication, perceptual motor response, and executive cognitive function in adults with alcohol use disorders: Preliminary findings","volume":"40","author":"Verplaetse","year":"2016","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib187","doi-asserted-by":"crossref","first-page":"15218","DOI":"10.1073\/pnas.2435171100","article-title":"Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans","volume":"100","author":"Wallner","year":"2003","journal-title":"Proceedings of the National Academy of Sciences U S A"},{"key":"10.1016\/bs.irn.2024.03.005_bib188","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","article-title":"Safety overview of post-marketing and clinical experience of sodium oxybate (xyrem): Abuse, misuse, dependence, and diversion","author":"Wang","year":"2009","journal-title":"Journal of Clinical Sleep Medicine 5"},{"key":"10.1016\/bs.irn.2024.03.005_bib189","first-page":"99","article-title":"Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: Results of a randomized trial","volume":"64","author":"Weinberg","year":"2008","journal-title":"The Journal of Trauma"},{"key":"10.1016\/bs.irn.2024.03.005_bib190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1060028014555859","article-title":"Evaluation of\u00a0adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome","volume":"49","author":"Wong","year":"2015","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/bs.irn.2024.03.005_bib191","unstructured":"World Health Organization (2012). Gamma-hydroxybutyric acid (GHB)\u2014Critical review report. \u3008https:\/\/kipdf.com\/gamma-hydroxybutyric-acid-ghb-critical-review-report-expert-committee-on-drug-de_5ac4e7c91723dd210d0a315e.html\u3009 Accessed 6.05.22."},{"key":"10.1016\/bs.irn.2024.03.005_bib192","unstructured":"World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV\/AIDS (2004). Substitution maintenance therapy in the management of opioid dependence and HIV\/AIDS prevention: WHO\/UNODC\/UNAIDS position paper. B."},{"key":"10.1016\/bs.irn.2024.03.005_bib193","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.celrep.2018.04.062","article-title":"Nicotinic cholinergic receptors in VTA glutamate neurons modulate excitatory transmission","volume":"23","author":"Yan","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/bs.irn.2024.03.005_bib194","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuron.2017.12.022","article-title":"Nucleus accumbens subnuclei regulate motivated behavior via direct inhibition and disinhibition of VTA dopamine subpopulations","volume":"97","author":"Yang","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2024.03.005_bib195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1530-0277.1999.tb04041.x","article-title":"Clinical use of benzodiazepines and decreased memory activation in anxious problem drinkers","volume":"23","author":"Zack","year":"1999","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.03.005_bib196","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1530-0277.2008.00700.x","article-title":"Development and pilot validation of computer-assisted self-infusion of ethanol (CASE): A new method to study alcohol self-administration in humans","volume":"32","author":"Zimmermann","year":"2008","journal-title":"Alcoholism, Clinical and Experimental Research"}],"container-title":["International Review of Neurobiology","The neurobiology of alcohol use disorder: Neuronal mechanisms, current treatments and novel developments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:21:09Z","timestamp":1762230069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443141645"],"references-count":196,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.03.005","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2024]]}}}